1-3 of 3
Fang Tang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4843.
https://doi.org/10.1182/blood-2024-204401
Published: 2024
Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4845.
https://doi.org/10.1182/blood-2023-184373
Published: 2023
Journal Articles

ATM-dependent spontaneous regression of early Eμ- myc –induced murine B-cell leukemia depends on natural killer and T cells

J. Ludovic Croxford, Melissa Li Fang Tang, Meng Fei Pan, Caleb Weihao Huang, Neha Kamran, Cindy Meow Ling Phua, Wee Joo Chng, Siok Bian Ng, David H. Raulet, Stephan Gasser
Journal: Blood
Blood (2013) 121 (13): 2512–2521.
https://doi.org/10.1182/blood-2012-08-449025
Published: 2013
Includes: Supplemental data